The International Journal of Neuropsychopharmacology
September 1, 2026
N Hartman, D Ivkic, M C Dorczok et al.
Neuropsychiatric manifestations of Long COVID (LC) frequently include post-exertional malaise (Cheng et al. , 2025), fatigue, cognitive dysfunction and impairment, sleep disturbances, post-traumatic stress, autonomic dysregulation, pain, inner tension, psychomotor retardation, aberrations in appetite and weight (Badenoch et al. , 2022; O'Mahoney et al. , 2025), showing substantial clinical and...
European Psychiatry
June 23, 2026
Maximilian Preiß, Valentin Popper, Luna Helene Charlotte Faber et al.
An abstract is not available for this content so a preview has been provided. As you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
European Psychiatry
June 16, 2026
A.H. Young, Lucie Bartova, N. Cardoner et al.
An abstract is not available for this content so a preview has been provided. As you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Frontiers in Psychiatry
2026
C M Diendorfer, C Bum, Ana Weidenauer et al.
Schizophrenia (SCZ) is a severe psychiatric condition characterized by positive symptoms such as hallucinations or delusions, as well as negative symptoms such as apathy, anhedonia and avolition. Given their chronic nature and limited response to current treatments, managing negative symptoms is a significant challenge for healthcare providers. Furthermore, many individuals with SCZ suffer from...
Frontiers in Psychiatry
August 30, 2024
Glenn Hartelius, Sherry-Anne Muscat, Lucie Bartova
protocols are designed to integrate and harness the full range of ketamine's intrinsic properties, ketamine therapies can realize their full potentials [3], possibly leading to improved outcomes in broader patient populations. Our first paper, "The Montreal model: An integrative biomedical-psychedelic approach to ketamine for severe treatment-resistant depression," takes this path toward...
Frontiers in Psychiatry
August 14, 2023
Glenn Hartelius, Sherry-Anne Muscat, Lucie Bartova
4 citations
EDITORIAL article Front. Psychiatry, 14 August 2023Sec. Psychopharmacology Volume 14 - 2023 | https://doi.org/10.3389/fpsyt.2023.1246891
European Neuropsychopharmacology
August 2018
Lucie Bartova, Konstantinos Papageorgiou, Ivan Milenkovic et al.
Rapid anti-suicidal and antidepressant effects of ketamine have repeatedly been confirmed in unipolar and bipolar depression. Although meaningful antidepressant efficacy of ketamine has also been shown in depressed patients with a history of psychotic symptoms, its administration in psychotic disorders has largely been neglected due to its potential to exacerbate dissociative or psychotic...
European Psychiatry
April 1, 2017
Lucie Bartova, Ana Weidenauer, Markus Dold et al.
IntroductionTreatment resistant depression (TRD) affecting approximately 10–30% of all depressed patients often remains misdiagnosed and undertreated, leading to a higher risk of relapse and suicide. Electroconvulsive therapy (ECT) and sub-anesthetic ketamine have repeatedly shown to be effective in the TRD population. Administering ketamine as an anesthetic component to augment antidepressant...
International Journal of Psychiatry in Clinical Practice
March 2017
Christoph Kraus, Ulrich Rabl, Thomas Vanicek et al.
Clinical trials demonstrated that ketamine exhibits rapid antidepressant efficacy when administered in subanaesthetic dosages. We reviewed currently available literature investigating efficacy, response rates and safety profile. Twelve studies investigating unipolar, seven on bipolar depression were included after search in medline, scopus and web of science. Randomized, placebo-controlled or...